Total Payments
$805,135
2024 Payments
$62,970
Companies
31
Transactions
170
Medicare Patients
7,450
Medicare Billing
$1.2M
Payment Breakdown by Category
Research$773,918 (96.1%)
Consulting$26,091 (3.2%)
Food & Beverage$4,367 (0.5%)
Travel$655.30 (0.1%)
Education$104.08 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $773,918 | 45 | 96.1% |
| Consulting Fee | $26,091 | 10 | 3.2% |
| Food and Beverage | $4,367 | 108 | 0.5% |
| Travel and Lodging | $655.30 | 6 | 0.1% |
| Education | $104.08 | 1 | 0.0% |
Payments by Type
Research
$773,918
45 transactions
General
$31,217
125 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valeant Pharmaceuticals North America LLC | $409,480 | 12 | $0 (2017) |
| Bausch Health US, LLC | $158,438 | 8 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $92,331 | 26 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $63,825 | 3 | $0 (2024) |
| SANOFI US SERVICES INC. | $42,098 | 1 | $0 (2024) |
| LEO Pharma Inc. | $16,403 | 16 | $0 (2020) |
| LEO Pharma AS | $6,504 | 4 | $0 (2018) |
| Eli Lilly and Company | $5,245 | 1 | $0 (2023) |
| Biofrontera Inc. | $4,594 | 7 | $0 (2021) |
| UCB, Inc. | $3,176 | 6 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $62,970 | 6 | SANOFI US SERVICES INC. ($42,098) |
| 2023 | $56,830 | 16 | E.R. Squibb & Sons, L.L.C. ($43,342) |
| 2022 | $22,119 | 24 | Regeneron Pharmaceuticals, Inc. ($21,438) |
| 2021 | $15,760 | 26 | Regeneron Pharmaceuticals, Inc. ($15,000) |
| 2020 | $33,228 | 14 | Regeneron Pharmaceuticals, Inc. ($23,125) |
| 2019 | $95,233 | 27 | Bausch Health US, LLC ($66,647) |
| 2018 | $99,119 | 33 | Bausch Health US, LLC ($86,361) |
| 2017 | $419,877 | 24 | Valeant Pharmaceuticals North America LLC ($409,480) |
All Payment Transactions
170 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $42,097.80 | Research |
| Study: Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $148.15 | General |
| 11/15/2024 | Almirall LLC | Klisyri (Drug) | Food and Beverage | In-kind items and services | $49.60 | General |
| Category: Dermatology | ||||||
| 11/14/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | — | Food and Beverage | In-kind items and services | $187.04 | General |
| 05/02/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | — | Cash or cash equivalent | $20,467.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting • Category: Immunology | ||||||
| 04/23/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: DERMATOLOGY | ||||||
| 12/04/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $7,500.00 | Research |
| Study: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA • Category: ONCOLOGY | ||||||
| 10/12/2023 | E.R. Squibb & Sons, L.L.C. | SOTYKTU (Drug) | — | Cash or cash equivalent | $43,342.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting • Category: Immunology | ||||||
| 08/16/2023 | Ortho Dermatologics, a division of Bausch Health US, LLC | JUBLIA (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Podiatry | ||||||
| 08/14/2023 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: Inflammation & Immunology | ||||||
| 08/12/2023 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $47.74 | General |
| 08/11/2023 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $112.00 | General |
| Category: Neurology | ||||||
| 06/23/2023 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $128.63 | General |
| Category: Neurology | ||||||
| 05/02/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $29.04 | General |
| Category: Dermatology | ||||||
| 04/25/2023 | Eli Lilly and Company | — | — | In-kind items and services | $5,244.71 | Research |
| Study: AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | ||||||
| 04/25/2023 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $8.53 | General |
| 04/18/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $34.80 | General |
| Category: DERMATOLOGY | ||||||
| 03/21/2023 | Galderma Laboratories, L.P. | EPIDUO (Drug), TWYNEO | Food and Beverage | In-kind items and services | $100.90 | General |
| Category: ACNE | ||||||
| 03/19/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $58.77 | General |
| Category: Immunology | ||||||
| 03/17/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $119.80 | General |
| 03/08/2023 | PFIZER INC. | EUCRISA (Drug), CIBINQO, COMIRNATY | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: DERMATOLOGY | ||||||
| 03/07/2023 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $46.02 | General |
| Category: Inflammation | ||||||
| 12/06/2022 | Journey Medical Corporation | TargaDox (Drug) | Food and Beverage | In-kind items and services | $122.57 | General |
| Category: Dermatology | ||||||
| 11/28/2022 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $16.33 | General |
| Category: Immunology | ||||||
| 11/18/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $732.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| IIS 2015-1060-Markowitz | Valeant Pharmaceuticals North America LLC | $206,215 | 2 |
| 2015-1060 Markowitz | Bausch Health US, LLC | $84,270 | 5 |
| 2015-1060 Markowitz | Valeant Pharmaceuticals North America LLC | $80,923 | 3 |
| 2015-1060-Markowitz | Bausch Health US, LLC | $74,168 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | E.R. Squibb & Sons, L.L.C. | $63,809 | 2 |
| 2015-1060-Markowitz | Valeant Pharmaceuticals North America LLC | $53,786 | 1 |
| Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | SANOFI US SERVICES INC. | $42,098 | 1 |
| IIS2015-1060 Markowitz | Valeant Pharmaceuticals North America LLC | $40,000 | 1 |
| A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA | Regeneron Pharmaceuticals, Inc. | $37,813 | 8 |
| A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITOR THERAPY, OR WERE INTOLERANT OF PRIOR HEDGEHOG PATHWAY INHIBITOR THERAPY | Regeneron Pharmaceuticals, Inc. | $37,813 | 9 |
| 2015-1060VA | Valeant Pharmaceuticals North America LLC | $28,196 | 1 |
| A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA | Regeneron Pharmaceuticals, Inc. | $15,000 | 2 |
| AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | Eli Lilly and Company | $5,245 | 1 |
| A randomized, double blind, vehicle-co ntrolled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). | Biofrontera Inc. | $4,583 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,177 | 5,330 | $1.6M | $367,072 |
| 2022 | 23 | 1,960 | 4,678 | $1.4M | $344,491 |
| 2021 | 23 | 1,994 | 4,280 | $1.3M | $332,937 |
| 2020 | 17 | 1,319 | 1,951 | $637,984 | $141,102 |
Total Patients
7,450
Total Services
16,239
Medicare Billing
$1.2M
Procedure Codes
83
All Medicare Procedures & Services
83 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 519 | 1,386 | $611,251 | $147,728 | 24.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 353 | 586 | $212,839 | $51,073 | 24.0% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 64 | 94 | $110,224 | $28,499 | 25.9% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 63 | 93 | $93,320 | $22,803 | 24.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 298 | 462 | $110,040 | $19,843 | 18.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 124 | 124 | $71,497 | $17,140 | 24.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 156 | 348 | $62,477 | $16,245 | 26.0% |
| 17281 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 31 | 73 | $46,685 | $10,876 | 23.3% |
| 13120 | Complicated repair of wound of scalp, arms, or legs, 1.1-2.5 cm | Office | 2023 | 24 | 31 | $39,473 | $10,146 | 25.7% |
| 10040 | Acne surgery | Office | 2023 | 45 | 68 | $28,207 | $7,209 | 25.6% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 34 | 60 | $52,205 | $6,835 | 13.1% |
| 13100 | Complicated repair of wound of trunk, 1.1-2.5 cm | Office | 2023 | 18 | 24 | $29,214 | $6,596 | 22.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 202 | 987 | $23,263 | $6,046 | 26.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 32 | 374 | $18,338 | $4,687 | 25.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 41 | 53 | $16,575 | $4,037 | 24.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 69 | 78 | $15,375 | $3,670 | 23.9% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 27 | 42 | $8,525 | $1,613 | 18.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 15 | 17 | $6,899 | $1,540 | 22.3% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 32 | 374 | $1,745 | $441.72 | 25.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 30 | 56 | $183.04 | $43.61 | 23.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 460 | 1,210 | $543,889 | $133,511 | 24.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 301 | 474 | $178,442 | $43,076 | 24.1% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2022 | 62 | 99 | $116,524 | $30,424 | 26.1% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2022 | 62 | 99 | $104,036 | $25,517 | 24.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 256 | 393 | $96,383 | $17,861 | 18.5% |
About Orit Markowitz
Orit Markowitz is a Dermatology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1215121538.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Orit Markowitz has received a total of $805,135 in payments from pharmaceutical and medical device companies, with $62,970 received in 2024. These payments were reported across 170 transactions from 31 companies. The most common payment nature is "" ($773,918).
As a Medicare-enrolled provider, Markowitz has provided services to 7,450 Medicare beneficiaries, totaling 16,239 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 83 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location New York, NY
- Active Since 08/29/2007
- Last Updated 03/17/2008
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1215121538
Products in Payments
- JUBLIA (Drug) $356,347
- JUBLIA EFINACONAZOLE (Drug) $211,379
- LIBTAYO (Biological) $90,625
- SOTYKTU (Drug) $43,342
- Sotyktu (Drug) $20,483
- PICATO (Drug) $6,724
- ENSTILAR (Drug) $4,940
- Ameluz (Drug) $4,520
- DUPIXENT (Biological) $1,281
- SILIQ (Drug) $285.97
- COSENTYX (Biological) $277.10
- VYVGART HYTRULO (Drug) $240.63
- VYVGART (Drug) $205.78
- TREMFYA (Drug) $172.63
- Erivedge (Biological) $144.35
- TargaDox (Drug) $122.57
- Levulan (Drug) $104.08
- EPIDUO (Drug) $100.90
- AMELUZ (Drug) $74.07
- EUCRISA (Drug) $63.27
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in New York
David Cohen, M.d, M.D
Dermatology — Payments: $3.1M
Dermatology $3.1M
Dr. Amy Wechsler, M.d, M.D
Dermatology — Payments: $2.8M
Dermatology $2.8M
Dr. Alexandra Golant, M.d, M.D
Dermatology — Payments: $2.7M
Dermatology $2.7M
Emma Guttman, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Dr. Joshua Zeichner, Md, MD
Dermatology — Payments: $2.1M
Dermatology $2.1M
Dr. Mark Lebwohl
Dermatology — Payments: $2.0M
Dermatology $2.0M